CXCR4 and schwannoma: In this pilot cohort, [68Ga]Pentixafor PET/CT was able to detect all schwannomas with sufficient tumor-to-background and tumor-to-blood pool ratios and matched with membranous CXCR4 expression as assessed by immunohistochemistry.